Phase 1/2, Two-Part, Open-Label Dose-Escalation And Double-Blind, Placebo-Controlled Dose-Expansion Study With An Open-Label Extension To Evaluate The Safety And Efficacy Of Ata188 In Subjects With Progressive Multiple Sclerosis
Posted Date: Jun 22, 2021
- Investigator: Aram Zabeti
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
This is a multicenter, 2-part study in adult subjects with progressive forms of MS with an open-label, single-arm sequential dose-escalation period (Part 1) and a double-blind, randomized, placebo-controlled dose-expansion period (Part 2) and OLE, both of which may be initiated at the sponsor’s discretion, based on a review of data from the dose-escalation cohorts. This study will evaluate the safety and efficacy of ATA188 administered by intravenous (IV) infusion.
Participant Must Be Between 18-66 And Have A History Of Progressive Form Of Ms (Ppms Or Spms).
Progressive Multiple Sclerosis, Neurology, Ms
For More Information: